Hot Features
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanu... DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.27 | -1.6780609074 | 16.09 | 17.245 | 15.24 | 387731 | 16.02109075 | DR |
| 4 | -1.56 | -8.97583429229 | 17.38 | 18.5 | 15.24 | 326139 | 16.33664043 | DR |
| 12 | -5.15 | -24.5588936576 | 20.97 | 23.038 | 15.24 | 261560 | 18.32919168 | DR |
| 26 | -3.22 | -16.9117647059 | 19.04 | 25.4 | 15.24 | 301321 | 19.94267401 | DR |
| 52 | 5.67 | 55.8620689655 | 10.15 | 26.185 | 8.51 | 251365 | 18.54193775 | DR |
| 156 | 13.93 | 737.037037037 | 1.89 | 26.185 | 0.42 | 257239 | 7.63922481 | DR |
| 260 | 10.02 | 172.75862069 | 5.8 | 26.185 | 0.42 | 261163 | 5.41207784 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.